Caris Life Sciences, Inc.

Caris is an AI TechBio company and precision medicine pioneer that develops and commercializes solutions to transform healthcare using molecular information and artificial intelligence/machine learning algorithms. Founded in 2008, the company focuses on oncology and serves the clinical, academic, and biopharma markets. Caris's portfolio includes comprehensive, proprietary molecular profiling solutions and a multi-modal clinico-genomic dataset in oncology. As of December 31, 2025, Caris has performed sequencing on over 1,000,000 cases. The company's platform leverages next-generation sequencing ("NGS"), artificial intelligence ("AI") and machine learning ("ML") technologies, and high-performance computing. This platform enables the development of advanced precision medicine diagnostic solutions for the entire cancer care continuum, including early detection, minimal residual disease ("MRD") tracking, therapy selection, and treatment monitoring, as well as the creation of molecular signatures and the discovery and development of novel precision medicine therapeutics. Caris's Molecular Intelligence product portfolio, focused on oncology, includes: (1) the MI Profile Platform, which offers whole exome sequencing ("WES")/whole transcriptome sequencing ("WTS") tissue-based molecular profiling solutions, (2) the Caris Assure Platform, providing WES/WTS blood-based molecular profiling solutions, and (3) the Precision Whole Genome Platform, offering whole genome sequencing ("WGS") blood- and tissue-based profiling solutions.